MaxCyte sees Q4 core revenue between $6.6M and $6.7M

* MaxCyte (MXCT [https://seekingalpha.com/symbol/MXCT]) on Monday said Q4 core revenue is expected to be between $6.6 million and $6.7 million.
* Core revenue for the full year is expected to be between $29.5 million and $29.6 million.
* Strategic Platform License (SPL) program-related revenue in the fourth quarter is expected to be between $0.4 million and $0.6 million.
* SPL program-related revenue for the full year is expected to be between $3.3 million and $3.5 million.
* Total cash, cash equivalents, and investments as of December 31, 2025, is expected to be approximately $155.6 million.
* MXCT +3.496% premarket to $1.48.
* Source: Press Release [https://seekingalpha.com/pr/20360547-maxcyte-announces-preliminary-unaudited-fourth-quarter-and-full-year-2025-financial-results]

MORE ON MAXCYTE

* MaxCyte, Inc. (MXCT) Q3 2025 Earnings Call Transcript [https://seekingalpha.com/article/4842835-maxcyte-inc-mxct-q3-2025-earnings-call-transcript]
* MaxCyte reports Q3 results [https://seekingalpha.com/news/4521258-maxcyte-reports-q3-results]
* MaxCyte outlines $17M–$19M annualized savings through restructuring while reiterating SPL revenue guidance [https://seekingalpha.com/news/4521043-maxcyte-outlines-17m-19m-annualized-savings-through-restructuring-while-reiterating-spl]
* Seeking Alpha’s Quant Rating on MaxCyte [https://seekingalpha.com/symbol/MXCT/ratings/quant-ratings]
* Historical earnings data for MaxCyte [https://seekingalpha.com/symbol/MXCT/earnings]